

British HIV Association/British Infection Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019

DH Dockrell^{1,2}, D O'Shea^{1,2}, JD Cartledge³, AR Freedman⁴

¹University of Edinburgh, UK; ²Regional Infectious Diseases Unit, NHS Lothian Infection Service, Edinburgh, UK; ³Mortimer Market Centre, London, UK; ⁴Cardiff University School of Medicine, UK

E-mail: freedman@cardiff.ac.uk

Keywords: *Candida albicans*, candidiasis, non-*albicans Candida*, oesophagitis

1 Methods

1.1 Guideline development process

Full details of the guideline development process, including conflict of interest policy, are outlined in the BHIVA guideline development manual which was last updated in 2014 (see <https://www.bhiva.org/file/jgCacHqmuxZFL/GuidelineDevelopmentManual.pdf>). The scope, purpose and guideline topics were agreed by the writing group. Questions concerning each guideline topic were drafted and a systematic literature review undertaken by an independent information scientist (Jacoby Patterson). The search questions (the populations, interventions, comparators and outcomes [PICO]), are outlined in Appendix 1, and the search strategy in Appendix 2. Details of the methodology can be found on the BHIVA website (<https://www.bhiva.org/file/5d514ec9b503d/OI-guidelines-methods-general.pdf>). For the current guidelines, PubMed, Medline, Embase and the Cochrane Library were searched for English language publications between January 2010 and March 2018, the period since the last candidiasis guidelines published by BHIVA. Searches were conducted using the following terms: HIV or AIDS and candidosis, candidiasis, *Candida* spp., *Candida albicans*, non-*albicans Candida*, oropharyngeal candidiasis, candida (o)esophagitis, vulvo(-)vaginal candidiasis or mucosal candidiasis. Abstracts from selected conferences (BHIVA, Conference on Retroviruses and Opportunistic Infections, Interscience Conference on Antimicrobial Agents and Chemotherapy and Infectious Diseases Society of America) were also searched for the same period. Articles already cited in the 2011 BHIVA/British Infection Association (BIA) guidelines for the treatment of opportunistic infection in HIV-seropositive individuals were also considered for the current guidelines. Definitions used are summarised in Appendix 3.

Appendix 4 outlines the literature selection process. In total, 1133 abstracts were initially screened by the information scientist and 355 identified on the basis of clinical relevance, match to the PICO questions and level of detail. Exclusion factors were non-human studies, case reports and insufficient detail to allow thorough assessment. The 355 identified abstracts were assigned to PICO questions and subsequently reviewed by at least three members of the writing group. Each PICO question was initially reviewed by one member of the writing team, with expertise in the field, who reviewed the papers for relevance, prioritising meta-analyses and randomised control trials where available. They provided an initial summary, compiling evidence and combining this with evidence collected in the last guideline. The individual summaries were then formatted into an initial draft guideline and all authors then reviewed the recommendations against the evidence and also had the opportunity to review the data and add additional evidence having reviewed the assembled abstracts. For each topic and healthcare question, summated evidence was then evaluated by all writing group members. Using the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system (see BHIVA website: <https://www.bhiva.org/BHIVA-guideline-development>), writing group members were responsible for assessing and grading the quality of evidence for predefined outcomes across studies and developing and grading the strength of recommendations. All writing group members received training in the use of the modified GRADE criteria.

Before final approval by the writing group, the guidelines were published online for public consultation and external peer reviews were commissioned. As part of this process, input was sought from the partner organisation BIA and from patient groups. The writing group responded to all points raised in the consultation and review.

2 Epidemiology of candidiasis

Candida spp. are common commensals in the general population and may be cultured from the oral cavity, gastrointestinal tract and genital tract of up to 75% of individuals [1]. Surveillance studies have consistently identified higher rates of mucosal carriage of *Candida* in men and women with HIV [2,3], with mucosal candidiasis representing the primary pathological manifestation. Oropharyngeal candidiasis is the commonest opportunistic infection to affect individuals with HIV and occurred in 80–90% of patients in the era prior to combination antiretroviral therapy (cART) [4,5]. In recent cohort reviews, the relative frequency of oropharyngeal candidiasis has remained high compared to other opportunistic infections despite reduction in the overall prevalence in association with cART [6,7]. According to NA-ACCORD cohort data from North America, oesophageal candidiasis was the leading opportunistic infection by 2010 with an incidence of 0.34 (0.29-0.38) events per 100 person-years in 2008–2010 [7].

In studies conducted from the era prior to cART to the current era, oesophageal candidiasis has been reported as the AIDS-defining indicator illness in 11–51% of cases [5,8-11]. The most recent of these studies, which examined late presenters with HIV, defined as those with CD4 counts <350 cells/mm³ or with an AIDS-defining illness, reported the highest contribution of oesophageal candidiasis [11].

Although vaginal colonisation by *Candida* occurs more frequently in women living with HIV, vulvovaginitis occurs sporadically, and is similar in nature to that observed in immunocompetent people [5]. Some studies have shown an increase in vulvovaginal candidiasis with HIV, but severity or recurrence is not increased and, unlike oropharyngeal candidiasis, there is no relationship with CD4 T cell count [12,13]. Therefore, the impact of HIV appears to be less for vulvovaginal than for oropharyngeal candidiasis. Invasive candidiasis (candidaemia) represents a growing nosocomial threat attributable to individual host factors (e.g. immunosuppression) and healthcare-related risk factors. People living with HIV are increasingly at risk in the context of undergoing intensive treatments for emerging comorbidities that expose them to HIV-independent candidaemia risk factors (e.g. central venous catheter placement or intensive care admission). Studies have not demonstrated good evidence of a further increased risk in people living with HIV in the presence of these HIV-independent risk factors, and management is recommended as for HIV-seronegative individuals [5,14-17]. Several reviews and guidelines cover management of this condition [14,16,17].

2.1 *Candida* spp. causing *Candida* infections in people living with HIV

Candida albicans remains the leading cause of *Candida* infections globally but the distribution of non-*albicans* *Candida* spp. shows geographical variation [18]. Non-*albicans* *Candida* spp. occur particularly in association with previous azole therapy and advanced immunosuppression [5]. HIV-specific data for oropharyngeal or vulvovaginal infections reflect the trends in international surveillance data; *C. albicans* remains most prevalent. The rates of non-*albicans* *Candida* spp. continue to rise to approximately 30% in many cohorts, influenced by geographical location and resource setting [3,19-21]. Recent US data suggest that *C. albicans* is responsible for 62–68% of oropharyngeal *Candida* spp. infections and 73% of vulvovaginal *Candida* spp. infections [2,22]. *C. glabrata* (17–21% of cases) and *C. dublinensis* (6–12%) are leading causes of non-*albicans* *Candida* infections in US and South African populations [22-24].

Antifungal azole resistance may be an intrinsic feature, as observed for fluconazole in *C. krusei*, or may be the result of evolution during recurrent drug exposure, as for fluconazole in *C. albicans* or *C. dublinensis* [5,16]. For some species such as *C. glabrata*, azole resistance may be induced by drug exposure but background resistance to fluconazole is also prevalent. Therefore, detection of *C. glabrata* should prompt treatment with an alternative agent unless fluconazole susceptibility is microbiologically demonstrated [16]. The increased prevalence of innately fluconazole-resistant *Candida* spp. and *Candida* spp. with reduced-susceptibility to echinocandins and many other antifungals highlights the need for accurate speciation and susceptibility testing [25-28]. *C. auris*, an inherently multidrug-resistant new *Candida* spp., has recently emerged as a cause of candidaemia; it is an infection control challenge, particularly in intensive care units and after surgery, but has not yet been linked with particular problems in HIV [29].

2.2 Risk factors for *Candida* infection in people living with HIV

The immunological response against *Candida* spp. at the gastrointestinal mucosa or on skin surfaces is highly dependent on T helper (Th)17 T cells [30]. This T cell subset is disproportionately depleted during the early stages of HIV-associated T cell decline and this disrupts host surveillance, favouring pathogenicity [31,32]. This in part reflects the fact that

the *Candida*-specific Th17 T cells are highly permissive to HIV infection [31]. Vulvovaginal candidiasis may be less influenced by Th17 T cell function and more influenced by dysbiosis and alterations in the vaginal pH. The oral microbiome also shows reduced diversity and increased *Candida* spp. colonisation in association with HIV-related immunosuppression, but these changes are at least partially reversible with cART [19,33,34]. Individuals receiving cART who have oesophageal candidiasis show evidence of impaired T cell responses to *C. albicans* even after 2 years of therapy. Thus, increased susceptibility due to impaired immunity may remain despite cART [35]. Clinical risk factors for oropharyngeal candidiasis other than immunosuppression in people living with HIV include injection drug misuse and tuberculosis. Other more general predisposing factors, not specifically related to HIV, include the presence of multispecies biofilms due to poor oral hygiene, dental caries, diabetes mellitus, use of inhaled/topical or systemic corticosteroids and poorly controlled gastro-oesophageal reflux disease (GORD), since *Candida* spp. thrive in an acidic environment. However, *Candida* spp. have also been found in the presence of proton pump inhibitors in some studies suggesting there may be an optimal pH level to inhibit growth [21,23,36].

3 Presentation

3.1 Clinical manifestations of mucosal candidiasis in people living with HIV

Oropharyngeal candidiasis is associated with worsening immunodeficiency [37] and in the absence of cART predicts the development of AIDS at a median of 25 months [38]. The most familiar clinical appearance of oropharyngeal candidiasis is of easily removable, curd-like white plaques, underneath which lies raw or bleeding mucosa (so-called 'pseudomembranous' candidiasis). Other oral presentations include: an erythematous form, with patchy reddening of the mucosa and depapillation of the dorsal surface of the tongue [39]; hyperplastic candidiasis, with white plaques that cannot be scraped away; and angular cheilitis with painful fissuring of the commissures. The predominant symptoms are sore mouth and throat, though the presentation may be asymptomatic with just the clinical appearance of oral candidiasis.

Vulvovaginal candidiasis in women living with HIV presents with similar features to that in women without HIV (vulvovaginitis with itching and curd-like exudate) [5,13,14,40]. Symptoms are non-specific and failure to respond to clinical treatment, associated with failure to detect *Candida* spp. on microbiological testing, should raise the possibility of an alternative diagnosis.

Most commonly the patient with oesophageal candidiasis complains of dysphagia and/or odynophagia. Respiratory symptoms such as increased phlegm production, chronic cough and hoarseness of voice are also common. With widespread use of cART and the decline in opportunistic infections, the main differential consideration for upper gastrointestinal symptoms in people living with HIV is not erosive oesophagitis due to GORD. Oesophageal candidiasis and GORD can also coexist; GORD is a risk factor for oesophageal candidiasis since *Candida* spp. thrive in acidic environments and can more easily invade damaged mucosa. In a prospective study, people living with HIV who underwent endoscopy to investigate upper gastrointestinal symptoms generally reported higher symptom scores for a range of upper gastrointestinal symptoms, but neither odynophagia nor dysphagia were predictive of oesophageal candidiasis [41]. Heartburn and acid regurgitation were in fact

more predictive of erosive oesophagitis in people living with HIV. Dysphagia, especially when not responsive to treatment of oesophageal candidiasis or associated with weight loss, should also raise the possibility of oesophageal carcinoma [42]. Although oesophageal carcinoma is not an AIDS-associated malignancy, people living with HIV who present with dysphagia, and in particular those with weight loss or factors associated with oesophageal cancer in people living with HIV, such as GORD, heavy alcohol use and cigarette smoking [42], should have investigations to exclude oesophageal carcinoma.

Oesophageal candidiasis without oropharyngeal evidence of plaques is uncommon and occurs in only a small number of cases in most studies [43]. Therefore, where a patient complains of typical symptoms in the absence of oropharyngeal candidiasis, other diagnoses such as GORD and malignancy must be considered. However, one recent study, conducted in the cART era, demonstrated that 55% of patients with oesophageal candidiasis had no manifestations of oropharyngeal *Candida*, 57% were deemed asymptomatic, and 31% had CD4 T cell counts >200 cells/mm³. This implies that some of the clinical features traditionally associated with oesophageal candidiasis in the era before widespread use of cART may be changing in an era of greater antiretroviral therapy coverage and lower degrees of immunosuppression [44].

4 Diagnosis

- ***Oral and oesophageal candidiasis are clinical diagnoses (Grade 2B, moderate quality of evidence).***
- ***Microbiological confirmation and susceptibility testing of *Candida* spp. is required when symptoms of candidiasis persist or recur during antifungal therapy to establish whether ongoing symptoms reflect an azole-resistant strain or an alternative diagnosis (Grade 1B, moderate quality of evidence).***
- ***Endoscopic diagnosis should be undertaken in patients with oesophageal symptoms without oropharyngeal candidiasis, in patients who do not respond to initial treatment, and in the case of relapse (Grade 1C, low quality of evidence).***

4.1 Role of microbiological confirmation of *Candida* spp. infection

Oropharyngeal and oesophageal candidiasis are clinical diagnoses, and microbiological confirmation has traditionally not been advised due to the likelihood of positive cultures in the absence of clinical disease. Recent studies highlight that, even in the era of widespread antiretroviral therapy, non-oral health specialists can accurately identify oropharyngeal candidiasis with 81–90% sensitivity and 92% specificity, which approaches the performance of microbiological detection [45]. This suggests that this approach is still reasonable for mucosal infections caused by *Candida* spp. There is increasing recognition that empiric antimicrobials and low-dose prophylaxis in settings of minimal risk promote resistance in fungi [46].

Candida cultures should be requested for individuals with persisting signs and symptoms of infection despite antifungal therapy or who experience recurrent infection. This will serve to identify the possibility of an azole-resistant infection or, in the context of negative cultures/poor response despite susceptible strains, will indicate the possibility of alternative or additional diagnoses. Recurrent oropharyngeal candidiasis occurs in the context of failure to establish immune reconstitution or the presence of persistent non-HIV-related risk factors

and has represented a primary driver for the selection of non-*albicans Candida* and of fluconazole-resistant species due to repeated antifungal exposure [24,28,47,48]. The goal of culture should be to speciate the *Candida* spp. to inform selection of antifungal therapy and to derive a sample for susceptibility testing. *C. krusei* is always fluconazole resistant and may be cross-resistant to itraconazole and other azoles. *C. glabrata* fluconazole sensitivity is more variable but *C. glabrata* infection emerges following antifungal exposure with many strains demonstrating fluconazole non-susceptibility [49].

4.2 Techniques used to establish microbiological diagnosis of *Candida* spp.

There are national standards for microbiological investigations providing detailed standard operating procedures for laboratories (see <https://www.gov.uk/government/collections/standards-for-microbiology-investigations-smi>). In brief, a swab of an active lesion from a typical oral site such as the palate or buccal mucosa or a vaginal swab will usually establish the diagnosis [50]. A wet-mount vaginal specimen with use of normal saline and 10% potassium hydroxide should be examined by microscopy for the presence of yeast cells and pseudohyphae. In cases of recurrent symptoms or poor or partial response, specimens should also be sent for culture. A vaginal self-swab is also an effective sample with high acceptance rates in studies of HIV-negative individuals [51]. In symptomatic patients without obvious lesions to swab, oral or vaginal rinse will establish the identity of colonising species to guide initial therapy [52,53]. In rare cases the absence of obvious lesions or failure to respond to initial therapy may suggest diagnostic uncertainty. This should prompt biopsy to exclude other diagnoses such as lichen planus. However, these biopsy specimens should be examined by microscopy with special fungal stains and also sent for culture.

Candida spp. may be cultured on selective media, although they are frequently detected on blood agar. Culture and reporting should follow national standards for microbiology investigation. Automated phenotypic analysis systems such as Vitek-2 are most often used for speciation but may have limitations against some non-*albicans Candida*. MALDI-TOF mass spectrometry-based proteomics techniques may be more rapid and increasingly are being used as alternatives. Candidaemia is diagnosed by blood culture and the presence of *Candida* in blood culture always indicates invasive disease. In all cases with invasive disease and for superficial swabs with unresponsive or recurrent infection the *Candida* isolate should be speciated and anti-fungal sensitivities performed [14]. Techniques used to supplement the diagnosis of invasive candidiasis, such as β -1,3-D-glucan detection, have no role for mucosal disease [50].

4.3 The role of endoscopy in the diagnosis of oesophageal candidiasis

Suspected oesophageal candidiasis can be treated empirically when other opportunistic infections or non-AIDS-related oesophageal syndromes are believed to be less likely diagnoses. Confirmation by endoscopy should be used in cases with symptoms of oesophageal candidiasis which fail to respond to initial therapy, cases without concomitant oropharyngeal candidiasis, or cases where an alternative oesophageal condition is suspected, such as oesophageal carcinoma in cases with dysphagia, where barium swallow may have been the initial investigation.

Endoscopy should reveal typical appearances such as white patches. Directed brushings or biopsy specimens can be sent for laboratory analysis as outlined above [54,43].

5 Treatment (Table 1)

- ***Fluconazole remains the preferred treatment option for oropharyngeal candidiasis on the basis of an updated Cochrane database systematic review [55] (Grade 1A, high quality of evidence).***
- ***Fluconazole and topical treatment are equally clinically effective at treating oropharyngeal candidiasis with azole-sensitive strains, but azole therapy is associated with a lower risk of relapse. Topical therapy can be considered as an alternative to fluconazole for mild oropharyngeal candidiasis when there is a low risk of relapse (Grade 1B, moderate quality of evidence).***
- ***Fluconazole is the recommended treatment for people living with HIV with moderate–severe oropharyngeal candidiasis or with oesophageal candidiasis and azole-sensitive strains (Grade 1A, high quality of evidence).***
- ***Topical therapy or oral fluconazole can be used to treat uncomplicated vulvovaginal candidiasis with regimens similar to those used for HIV-negative populations (Grade 1A, high quality of evidence).***

5.1 Treatment of oropharyngeal candidiasis

An important component of therapy is to address any modifiable risk factors to prevent recurrence and this should be combined with specific therapy. Good oral hygiene and meticulous regular removal of oral biofilms (dental plaque) is a key component of the management of oral infection as biofilms are inherently resistant to antimicrobial therapy alone. The findings of an updated Cochrane database systematic review in 2010 support the conclusion that fluconazole therapy is consistently associated with superior rates of mycological cure when compared to topical therapy for the treatment of oropharyngeal candidiasis [55]. Fluconazole (100–200 mg/day) is the most commonly selected orally absorbable systemic azole against oropharyngeal candidiasis and should be prescribed for 7–14 days [56–59]. Fluconazole 100 mg can be used for 7 days in first episodes with the higher dose or more prolonged duration reserved for severe disease with a fluconazole-sensitive strain or cases of relapse after previous fluconazole treatment. In the latter cases, culture and sensitivity should exclude fluconazole resistance thereby supporting ongoing fluconazole therapy.

Topical therapy may be used in mild oropharyngeal candidiasis. It is associated with slower clearance of yeast from the mouth, a higher relapse rate and reduced tolerability [60,61]. Therefore, we recommend this as an alternative option to fluconazole only in mild cases without a history of frequent recurrence and when there may be reasons to consider an alternative to fluconazole, such as in the setting of fluconazole intolerance or fluconazole-refractory *C. albicans*. Topical treatment is usually administered as nystatin (oral suspension of 100,000 units/mL, 5 mL four times daily for 7–14 days). Alternative topical agents where available through specialist pharmacies, include amphotericin (10 mg lozenges four times daily, or oral solution) [62], clotrimazole pessaries (100 mg, sucked rather than swallowed [Cartledge JD, personal communication]) and clotrimazole troches (i.e. small dissolvable lozenges, 10 mg five times daily) [60,61], all administered for 7–14 days. A recent randomised clinical trial demonstrated that a miconazole buccal adhesive formulation,

50 mg applied over the canine fossa once daily, was non-inferior to clotrimazole troches [63]. However, there is a lack of data on drug–drug interactions or the effects on QT interval with agents such as clotrimazole and they should only be used with expert advice when benefits are considered to outweigh potential risks.

Clinical response rates (using a range of definitions) in these studies with topical therapy ranged from 61–94% and, where directly compared, have been comparable to rates with fluconazole. However, as above, the therapies have been associated with lower rates of mycological cure and greater relapse rates [60-63]. In addition to topical or systemic antifungal therapy, emerging evidence regarding the role of biofilm formation in oropharyngeal candidiasis emphasises the need for mechanical disruption through good brushing and the use of 0.2% chlorhexidine mouthwash [64]. This is especially important for denture wearers who are at particular risk of fluconazole resistance due to biofilm formation which can promote resistance development [22,64].

Empiric treatment should be limited to cases with clear clinical features together with associated risk factors. Fluconazole or topical therapy remain the choices for initial empirical therapy. Other agents discussed below should only be used after consultation with an infectious disease or clinical microbiology specialist and in specific circumstances.

5.2 Treatment of oesophageal candidiasis

As with oropharyngeal candidiasis, attention should focus on any modifiable risk factors in addition to specific therapy for candidiasis. Both fluconazole and itraconazole have demonstrated efficacy in the treatment of oesophageal candidiasis, with fluconazole providing greater short-term response (2-week cure rates of approximately 80% in the era prior to cART) [65,66]. Fluconazole 200–400 mg once daily for 14–21 days remains the preferred option, with 14-day courses of 200 mg used for milder disease [66].

Although itraconazole has been used as an alternative, better bioavailability and fewer drug–drug interactions ensure fluconazole remains the preferred option. When itraconazole is used it should be administered as cyclodextrin (oral) solution, because the bioavailability of capsules is less than that of the oral solution and is more dependent on gastric acid to facilitate absorption. Achlorhydria, which is associated with advanced HIV disease, impairs the absorption of the capsule formulation and unpredictable drug levels reduce efficacy [67,68]. Itraconazole oral solution has better bioavailability than the capsule formulation, but still shows variability in levels, as its absorption is also facilitated by gastric acidity and its bioavailability is reduced in comparison to fluconazole [69]. Therefore, even with oral solution itraconazole absorption is unpredictable, especially in patients with low CD4 T cell counts and those requiring systemic antacid preparations, and treatment with fluconazole is the preferred option in most cases. Proton pump inhibitors commonly prescribed empirically for oesophageal symptoms also inhibit the activity of fluconazole in cell culture models and withholding these during treatment of the acute stages of oesophageal or severe oropharyngeal candidiasis should be considered [70]. If a short period without acid suppression is not an option, shorter-acting treatment such as antacid therapy or use of an H₂-receptor antagonist (e.g. ranitidine) may be an option.

Itraconazole is metabolised via cytochrome P450 enzymes and therefore should not be co-prescribed with hepatic enzyme-inducing agents such as rifamycins. Fluconazole is excreted

predominantly unchanged in the urine and is therefore the azole of choice in patients requiring treatment with such enzyme inducers. It is advisable to use fluconazole, as the least hepatotoxic azole preparation, in patients with liver disease, although treatment with an echinocandin can also be considered (see below). In exceptional circumstances in patients who cannot tolerate an oral preparation, fluconazole 400 mg once daily intravenously is an option, although this requires discussion with an infection specialist.

5.3 Treatment of fluconazole-refractory oropharyngeal or oesophageal candidiasis

In cases where the patient has not developed a symptomatic response and where follow-up cultures are negative, alternative diagnoses should be considered rather than repeated courses of therapy. Where there is clinical or microbiological persistence of oropharyngeal candidiasis, poor adherence to therapy, dry mouth with poor local drug penetration for oral therapy or poor absorption of oral therapy may be considerations. The anti-fungal agents discussed below should only be used in consultation with an infectious disease or other infection specialist. These are reserved for refractory disease or special circumstances including intolerance to multiple agents or inability to take oral therapy. Itraconazole, voriconazole and posaconazole have variable bioavailability. Although there may be some topical effects of oral suspensions of itraconazole or posaconazole, the contribution of this is unknown in oropharyngeal or oesophageal candidiasis. Therapeutic drug monitoring is therefore usually required to check for therapeutic levels of itraconazole, voriconazole and posaconazole. A newer sustained release tablet formulation of posaconazole increases bioavailability but will not allow for any topical effects that the oral solution may have and its role in the therapy of oropharyngeal candidiasis is unknown. The capsule formulation of itraconazole should not be used as outlined above. Itraconazole, posaconazole and voriconazole have increased drug–drug interactions in comparison with fluconazole which also limits their use and mandates checking for drug–drug interactions via the Liverpool HIV Drug Interactions website (<https://www.hiv-druginteractions.org/checker>) or similar websites.

Itraconazole oral solution (200 mg twice daily) has demonstrated efficacy against oropharyngeal candidiasis [71-73]. It is reserved for a minority of cases due to poorer bioavailability and greater drug–drug interactions, in comparison with fluconazole (as mentioned above). It is reserved for use when fluconazole resistance is demonstrated but the strain is susceptible to itraconazole, when there is recurrence/fluconazole refractory disease in the absence of documented fluconazole resistance (e.g. when theoretical concerns about local drug levels might warrant a trial of an oral solution, as might arise in a patient with dry mouth), or in rare cases where there is intolerance to fluconazole. Clinical response rates for fluconazole-refractory disease with itraconazole oral solution were greater than 50% in the pre-cART era [73]. Posaconazole oral suspension is an alternative and has been associated with improved sustained mycological responses in comparison with fluconazole [74]. The duration of therapy can be extended to 28 days in refractory disease.

All azole regimens, other than low-dose fluconazole (100 mg daily or less), require regular monitoring of liver function tests, initially in the first week and then monthly or bi-monthly if prolonged beyond 14 days. Reports of congestive heart failure in patients receiving itraconazole (but not fluconazole) mean this therapy should be avoided in patients with

congestive heart failure [75]. Therapeutic drug monitoring is required when using itraconazole, voriconazole or posaconazole, as outlined above.

Occasionally patients may be intolerant to both topical therapy and oral fluconazole or demonstrate lack of response to oral fluconazole or other azoles because of poor adherence to or poor absorption of treatment. In these cases options can include fluconazole 400 mg once daily intravenously or the intravenous therapies outlined below for fluconazole-refractory oesophageal candidiasis.

There are a number of antifungal drugs that can be considered for the treatment of fluconazole-refractory oesophageal disease [76]. As is the case for oropharyngeal candidiasis, non-response should raise concerns about an alternative diagnosis and should lead to early endoscopy if not already performed. Alternatives to fluconazole should be used only with the input of an appropriate infection specialist. Alternatives to itraconazole (discussed above) for refractory oesophageal candidiasis include the azoles posaconazole, voriconazole and isavuconazole. Use of posaconazole and voriconazole requires therapeutic drug monitoring to limit toxicity and to check for adequate systemic absorption when used for oesophageal candidiasis [76], while the role of therapeutic drug monitoring for the newer agent isavuconazole is still being determined. As outlined above there are many drug–drug interactions between these azoles and antiretroviral agents (Table 2) or other agents administered to people living with HIV. The potential for drug–drug interactions involving these azoles and other agents should always be checked prior to administration (<https://www.hiv-druginteractions.org/checker>).

Posaconazole has demonstrated efficacy against oropharyngeal/oesophageal candidiasis, including candidiasis refractory to fluconazole/itraconazole [74,77]. More recently isavuconazole orally in regimens of 200 mg loading dose followed by 50 mg once daily or 400 mg loading dose followed by 400 mg once weekly have been shown to be non-inferior to fluconazole 100 mg once daily with comparable tolerability in patients with uncomplicated oesophageal candidiasis [78]. In comparison with voriconazole and posaconazole, isavuconazole has fewer drug–drug interactions, although it is still a CYP3A4 substrate and a moderate CYP3A4 inhibitor [79]. Isavuconazole may increase the exposure of medicines that are P-gp substrates, particularly those with a narrow therapeutic index which may require dose adjustment of colchicine, dabigatran, digoxin or other P-gp substrates with a narrow therapeutic index (<https://www.medicines.org.uk/emc/product/5069/smpc>). Isavuconazole may also be better tolerated than some of these other azoles and is not known to cause the photosensitivity or neurotoxicity associated with voriconazole [79]. Voriconazole is also active againstazole-resistant strains [80] and was found in a randomised controlled trial to be as effective but more toxic than fluconazole [81]. Its greater toxicity profile means it should typically be reserved for cases where isavuconazole or posaconazole are not used. However, the broader spectrum of agents such as voriconazole, posaconazole and isavuconazole and the associated antimicrobial stewardship concerns combined with the greater potential for drug–drug interactions as compared to fluconazole, variability in drug levels and the potential for drug side effects means these azoles should only be used in exceptional circumstances with specialist input.

In other circumstances, such as azole resistance or intolerance, hepatotoxicity or inability to take an oral medication or an intravenous azole, it may be necessary to choose an intravenous non-azole formulation. In these unusual circumstances, options subject to susceptibility may include the echinocandins, caspofungin, micafungin and anidulafungin (see Table 1 for dosing information) or intravenous liposomal amphotericin B (3 mg/kg intravenously once daily) [76]. Treatment duration with these agents should be 14–21 days for oesophageal candidiasis with the 14-day regimen used as first line and longer durations reserved for slow response or relapse.

These agents have all demonstrated efficacy in randomised clinical trials in oesophageal candidiasis, although antimicrobial stewardship and the need to limit the use of broader spectrum antifungal therapies and intravenous formulations means their use should be reserved for specific cases. Examples would include cases where fluconazole therapy is ineffective or not tolerated, oral therapy cannot be administered, or where infection is due to organisms with reduced susceptibility to first-line agents (Grade 2B, moderate quality of evidence). In clinical trials of oesophageal candidiasis, caspofungin was as effective but less toxic than amphotericin B [82] and was active against fluconazole-resistant strains [83]. Caspofungin, micafungin and anidulafungin have shown efficacy (variously defined as endoscopic response with or without improvement in clinical symptoms) comparable to fluconazole in the treatment of oesophageal candidiasis [82-86]. Only micafungin has resulted in a relapse rate comparable to that of fluconazole; caspofungin demonstrated a trend towards, and anidulafungin was significantly associated with, a higher relapse rate [82,85,86]. Of note, interpretation of these differences is hampered by the different doses of fluconazole used in the different studies [76].

For fluconazole-refractory/non-susceptible oropharyngeal candidiasis a typical approach would initially involve the use of itraconazole followed by an alternative azole or an echinocandin if there are no azole options. For oesophageal candidiasis the approach would utilise itraconazole, posaconazole or isavuconazole (or possibly voriconazole) followed by an echinocandin.

5.4 Treatment of vulvovaginal candidiasis

Vulvovaginal candidiasis is classified as acute or recurrent. Vulvovaginal candidiasis is treated in the same way in people living with HIV as it is in the HIV-negative population. Topical azole therapy has been shown to be equivalent to oral therapy in a systematic review of uncomplicated vulvovaginal candidiasis [87]. The preferred topical agent is clotrimazole pessary 500 mg intravaginally. Oral therapy can be administered as a single dose of 150 mg fluconazole and is preferred in some guidelines (e.g. the British Association for Sexual Health and HIV [BASHH]: <https://www.bashhguidelines.org/current-guidelines/all-guidelines/>) with topical therapy listed as an alternative. For severe disease with extensive erythema, oedema, excoriation or fissuring the oral dose can be repeated after 72 hours. For recurrent disease the oral fluconazole dose can be administered every 72 hours for three doses and then weekly for 6 months. Vulvovaginal candidiasis due to non-*albicans* *Candida* spp. with reduced fluconazole susceptibility (e.g. *C. glabrata*) may be treated with nystatin pessaries 100,000 units (unlicensed, but may be obtained through pharmaceutical importers) vaginally for 14 days. Alternatives to nystatin therapy for

non-*albicans Candida* are vaginal cream containing 5 g 5-flucytosine combined with nystatin pessaries (as above), amphotericin pessaries 50 mg for 14 days, or topical boric acid 600 mg in gelatin capsules (not licensed). These data derive from HIV-seronegative individuals and small series only [88-90] (Grade 2B recommendation, moderate quality of evidence). Further information is available in the BASSH guidelines for vulvovaginal candidiasis (<https://www.bashguidelines.org/current-guidelines/all-guidelines/>).

5.5 Treatment of invasive candidiasis in people living with HIV

There are no clinical trial data to guide the treatment of invasive candidiasis in individuals living with HIV. In general, invasive candidiasis should be treated with systemic antifungal therapy as in other patient groups without neutropenia (Grade 1C, low quality of evidence). International guidelines (e.g. from the European Society of Clinical Microbiology and Infectious Diseases and from the Infectious Disease Society of America) have proposed standards of care for invasive candidiasis in this setting and should be consulted to determine treatment duration which is influenced by patient factors and specific sites of deep-seated infection [14,91]. There are also no specific data on the treatment of *C. auris* in people living with HIV and *C. auris* infections should also be treated in line with emerging guidance for HIV-negative populations.

6 Prophylaxis and impact of cART

- ***Routine prophylaxis for mucosal candidiasis is not recommended (Grade 1B, moderate quality of evidence).***
- ***cART is the major intervention that reduces the incidence of mucosal candidiasis (Grade 1A, high quality of evidence).***

6.1 Strategies to prevent mucosal candidiasis in patients with advanced HIV infection

Routine prophylaxis is not warranted and is associated with the emergence of resistance. As with other opportunistic infections, effective cART prevents relapses of symptomatic oropharyngeal or oesophageal candidiasis. Thus, the most successful strategy for managing patients with candidiasis is to commence cART [6,7]. Drug–drug interactions should be considered with regard to antiretroviral and antifungal agents (see Table 2). Systematic review and meta-analysis of the impact of cART on opportunistic infections in low- and middle-income countries confirms that cART dramatically reduces the incidence of mucosal candidiasis with oral candidiasis being one of the opportunistic infections with the greatest impact [6]. A case–control study in a high-income setting examining the risk of oesophageal candidiasis showed that cART is associated with a reduced odds ratio of oesophageal candidiasis [92]. There are rare reports of candidiasis associated with immune reconstitution inflammatory syndrome, including a case of *Candida* meningitis leading to fatal vasculitis [93]. Despite the dramatic decline in candidiasis (oesophageal and oropharyngeal) with cART, there remains a residual level in people living with HIV above that in HIV-seronegative individuals [7,11].

6.2 Role of continuous azole therapy

Ongoing prescription of azole antifungals between episodes of recurrent oropharyngeal candidiasis is not recommended, as this may be associated with emergence of azole-resistant candidiasis [94-96] (Grade 1C, low quality of evidence). In the pre-cART era, azole-unresponsive candidiasis was increasingly common in patients who had received prolonged prophylaxis with azole antifungals and was due to infection with either species other than *C. albicans* [97-99], such as *C. krusei* and *C. glabrata*, or resistant strains of *C. albicans* [100-103]. However, continuous thrice weekly fluconazole treatment did not lead to a significant increase in fluconazole-refractory oropharyngeal or oesophageal candidiasis in an open-label trial comparing this approach to episodic treatment in people living with HIV with access to cART [104].

6.3 Azole prophylaxis in malignancy

The role of azole therapy to limit fungal infection, including candidiasis, during treatment of malignancy is discussed in the BHIVA malignancy guidelines [105].

Table 1 Antifungal therapies for selected *Candida* infections

Candidiasis	Antifungal agent	Comment
Oropharyngeal	Fluconazole 100–200 mg once daily Topical therapies (various, see text)	Preferred therapy. Duration 7–14 days Mild disease only
Vulvovaginal	Fluconazole 150 mg single dose	Severe or complicated infection: fluconazole 150 mg every 72 hours x 3 doses
Oesophageal	Fluconazole 200–400 mg once daily	Preferred therapy. Duration 14–21 days
Fluconazole refractory/resistant/intolerant oropharyngeal	Itraconazole oral solution 200 mg twice daily Posaconazole oral suspension 400 mg twice daily for refractory, then 400 mg once daily Isavuconazole orally 200 mg loading dose then 100 mg once daily or 400 mg loading dose with 400 mg weekly orally	Duration for all therapies typically 14 days Avoid itraconazole in congestive heart failure Therapeutic drug monitoring with itraconazole, posaconazole and voriconazole Liver function test monitoring with itraconazole, posaconazole and voriconazole Note: posaconazole sustained release tablets have better bioavailability than oral solution but there are no specific data on its use in mucocutaneous candidiasis and if used doses differ from those used for oral solution
Fluconazole refractory/resistant/intolerant oesophageal	Itraconazole oral solution 200 mg twice daily Posaconazole oral suspension 400 mg twice daily on day 1 then 400 mg once daily orally Voriconazole 200 mg twice daily orally or 4 mg/kg intravenously twice daily Isavuconazole orally 200 mg loading dose then 100 mg once daily or 400 mg loading dose with 400 mg weekly	Posaconazole oral suspension should be taken with a meal to increase absorption Note: posaconazole tablets and suspension have different bioavailability and doses are not interchangeable Although bioavailability is superior with the oral tablet (300 mg twice daily on day 1 then 300 mg daily thereafter); there are limited data on its use in mucocutaneous candidiasis

	<p>Caspofungin 70 mg intravenous loading, then 50 mg intravenously once daily</p> <p>Micafungin 150 mg intravenously once daily</p> <p>Anidulafungin 200 mg intravenous loading then 100 mg once daily</p>	<p>Maintenance dose 70 mg intravenously once daily if body weight >80 kg</p>
--	--	---

Table 2 *Candida* infection treatment and antiretroviral drug interactions

Antifungal drug	Interaction with antiretroviral agent	Action required
Amphotericin	Tenofovir disoproxil fumarate	Caution – increased risk of renal toxicity with concurrent or recent use
Caspofungin	Efavirenz and nevirapine levels reduced	Maintenance caspofungin dose 70 mg once daily, if body weight >80 kg
Fluconazole	Zidovudine levels increased	Caution – monitor for adverse effects
	Nevirapine levels increased	Caution – monitor for adverse effects
	Rilpivirine levels likely to increase	Caution – monitor for adverse effects
	Cobicistat	Concentrations of fluconazole increase. Therapeutic monitoring should be considered
	Tenofovir alafenamide	Fluconazole may increase tenofovir alafenamide levels but dose tenofovir alafenamide according to concomitant antiretroviral agents
Isavuconazole	Tenofovir alafenamide levels may increase	Dose tenofovir alafenamide according to concomitant antiretroviral agents
	Lopinavir/ritonavir levels may decrease, isavuconazole levels may increase	Use with caution
	Efavirenz levels may be decreased	Not recommended to be used together
	Etravirine may decrease isavuconazole	Not recommended to be used together
Itraconazole	Ritonavir- or cobicistat-boosted protease inhibitors or integrase inhibitors may increase itraconazole and protease or integrase inhibitor exposure	Avoid high doses of itraconazole (>200 mg) Monitor for side effects
	Efavirenz, etravirine and nevirapine reduce itraconazole levels	Consider alternative, or increase dose Monitor clinical effect
	Maraviroc levels increased	Reduce maraviroc dose (150 mg twice daily)
	Rilpivirine levels likely to increase	Avoid co-administration
	Cobicistat increases itraconazole	Therapeutic monitoring required Itraconazole dose should not exceed 200 mg once daily
	Tenofovir alafenamide levels predicted to increase due to P-gp inhibition by itraconazole	Dose emtricitabine/tenofovir alafenamide at 200/10 mg once daily
Posaconazole	Efavirenz reduces posaconazole levels	Avoid combination unless benefit to patient outweighs risk
	Atazanavir unboosted, boosted with cobicistat or ritonavir – levels	Caution – additional monitoring for toxicity (bilirubin levels)

	potentially increased	
	Other protease inhibitors – levels possibly increased	Monitor for signs of increased toxicity
	Rilpivirine levels likely to increase	Caution – monitor for adverse effects
	Cobicistat increases posaconazole levels	Therapeutic monitoring required
Voriconazole	Efavirenz levels increased and voriconazole levels decreased	Not recommended to be used together. Seek HIV specialist pharmacist advice
	Etravirine and voriconazole levels are both increased	No dose adjustment required – monitor
	Lopinavir/ritonavir and other ritonavir-boosted protease inhibitors reduce voriconazole levels	Not recommended to be used together. Seek HIV specialist pharmacist advice
	Rilpivirine levels likely to increase	No dosage adjustment required – monitor
	Cobicistat may increase or decrease voriconazole levels	Co-administration is not advised unless the potential benefits are considered to outweigh the risks of unpredictable drug levels

Antiretroviral drugs, especially the non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted protease inhibitors (PIs), have several important drug–drug interactions. This table lists some examples of drug–drug interactions between antiretroviral and antifungal drugs. As the azole antifungal compounds are metabolised via the cytochrome P450 enzyme system they are likely to interact with both NNRTIs and PIs. There are few published data on potential drug interactions with the newer antifungal agents. Several azoles are predicted to inhibit P-gp which may increase levels of tenofovir alafenamide. As data and advice change frequently, this information should always be interpreted in conjunction with the manufacturer’s information (<https://www.medicines.org.uk/>). Other useful online reference sources include the Liverpool HIV Drug Interactions (<https://www.hiv-druginteractions.org/>) and the Toronto General Hospital (<https://hivclinic.ca/drug-information/drug-interaction-tables/>) websites.

7 References

- 1 Odds FC. *Candida and candidiasis*. 2nd edn. London, UK, Bailliere Tindall, 1988.
- 2 Merenstein D, Hu H, Wang C *et al*. Colonization by *Candida* species of the oral and vaginal mucosa in HIV-infected and noninfected women. *AIDS Res Hum Retroviruses* 2013; **29**: 30–34.
- 3 Li YY, Chen WY, Li X *et al*. Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China. *BMC Infect Dis* 2013; **13**: 46.
- 4 Samaranayake LP, Holmstrunp P. Oral candidiasis and human immunodeficiency virus infection. *J Oral Pathol Med* 1989; **18**: 554–564.
- 5 Lortholary O, Petrikos G, Akova M *et al*. ESCMID* guideline for the diagnosis and management of *Candida* diseases 2012: patients with HIV infection or AIDS. *Clin Microbiol Infect* 2012; **18 Suppl 7**: 68–77.
- 6 Low A, Gavriilidis G, Larke N *et al*. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: a systematic review and meta-analysis. *Clin Infect Dis* 2016; **62**: 1595–1603.
- 7 Buchacz K, Lau B, Jing Y *et al*. Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000-2010. *J Infect Dis* 2016; **214**: 862–872.
- 8 Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations and trends. *AIDS* 1987; **1**: 175–182.
- 9 Achenbach CJ, Harrington RD, Dhanireddy S *et al*. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. *Clin Infect Dis* 2012; **54**: 424–433.
- 10 Grabar S, Lanoy E, Allavena C *et al*. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. *HIV Med* 2008; **9**: 246–256.
- 11 Tominski D, Katchanov J, Driesch D *et al*. The late-presenting HIV-infected patient 30 years after the introduction of HIV testing: spectrum of opportunistic diseases and missed opportunities for early diagnosis. *HIV Med* 2017; **18**: 125–132.
- 12 Ohmit SE, Sobel JD, Schuman P *et al*. Longitudinal study of mucosal *Candida* species colonization and Candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. *J Infect Dis* 2003; **188**: 118–127.
- 13 Sobel JD. Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. *Int J STD AIDS* 2002; **13**: 358–362.
- 14 Pappas PG, Kauffman CA, Andes DR *et al*. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016; **62**: e1–50.
- 15 Kullberg BJ, Arendrup MC. Invasive candidiasis. *N Engl J Med* 2015; **373**: 1445–1456.
- 16 Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. *Lancet Infect Dis* 2011; **11**: 142–151.
- 17 Colombo AL, de Almeida Júnior JN, Slavin MA. *Candida* and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. *Lancet Infect Dis* 2017; **17**: e344–e356.
- 18 Pfaller MA, Moet GJ, Messer SA *et al*. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among *Candida* bloodstream

- infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). *J Clin Microbiol* 2011; **49**: 396–399.
19. Lin JN, Lin CC, Lai CH *et al.* Predisposing factors for oropharyngeal colonization of yeasts in human immunodeficiency virus-infected patients: a prospective cross-sectional study. *J Microbiol Immunol Infect* 2013; **46**: 129–135.
 20. Mushi MF, Bader O, Taverne-Ghadwal L *et al.* Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. *J Oral Microbiol* 2017; **9**: 1317579.
 21. Thanyasrisung P, Kesakomol P, Pipattanagovit P *et al.* Oral Candida carriage and immune status in Thai human immunodeficiency virus-infected individuals. *J Med Microbiol* 2014; **63**: 753–759.
 22. Patel PK, Erlandsen JE, Kirkpatrick WR *et al.* The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy. *AIDS Res Treat* 2012; **2012**: 262471.
 23. Owotade FJ, Patel M, Ralephenya TR, Vergotine G. Oral Candida colonization in HIV-positive women: associated factors and changes following antiretroviral therapy. *J Med Microbiol* 2013; **62**: 126–132.
 24. Zhang L, She X, Merenstein D *et al.* Fluconazole resistance patterns in Candida species that colonize women with HIV infection. *Curr Ther Res Clin Exp* 2014; **76**: 84–89.
 25. Alexander BD, Johnson MD, Pfeiffer CD *et al.* Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. *Clin Infect Dis* 2013; **56**: 1724–1732.
 26. Perlin DS, Shor E, Zhao Y. Update on antifungal drug resistance. *Curr Clin Microbiol Rep* 2015; **2**: 84–95.
 27. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? *Curr Opin Infect Dis* 2014; **27**: 484–492.
 28. Lortholary O, Desnos-Ollivier M, Sitbon K *et al.* Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. *Antimicrobial Agents Chemother* 2011; **55**: 532–538.
 29. Schelenz S, Hagen F, Rhodes JL *et al.* First hospital outbreak of the globally emerging Candida auris in a European hospital. *Antimicrob Resist Infect Control* 2016; **5**: 35.
 30. Puel A, Cypowyj S, Bustamante J *et al.* Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. *Science* 2011; **332**: 65–68.
 31. Liu F, Fan X, Auclair S *et al.* Sequential dysfunction and progressive depletion of Candida albicans-specific CD4 T cell response in HIV-1 infection. *PLoS Pathog* 2016; **12**: e1005663.
 32. Cassone A, Cauda R. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. *AIDS* 2012; **26**: 1457–1472.
 33. Li Y, Saxena D, Chen Z *et al.* HIV infection and microbial diversity in saliva. *J Clin Microbiol* 2014; **52**: 1400–1411.
 34. Mushi MF, Mtemisika CI, Bader O *et al.* High oral carriage of non-albicans Candida spp. among HIV-infected individuals. *Int J Infect Dis* 2016; **49**: 185–188.
 35. Stuehler C, Bernardini C, Elzi L *et al.* Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy. *AIDS* 2016; **30**: 1923–1933.

36. Wu CJ, Lee HC, Yang YL *et al.* Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter. *Clin Microbiol Infect* 2012; **18**: 485–490.
37. Kaslow RA, Phair JP, Friedman HB *et al.* Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency: a report from the Multicenter AIDS Cohort Study. *Ann Intern Med* 1987; **107**: 474–480.
38. Dodd CL, Greenspan D, Katz MH *et al.* Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. *AIDS* 1991; **5**: 1339–1343.
39. Schiødt M, Bakilana PB, Hiza JF *et al.* Oral candidiasis and hairy leukoplakia correlate with HIV infection in Tanzania. *Oral Surg Oral Med Oral Pathol* 1990; **69**: 591–596.
40. United Kingdom National Guideline on the Management of Vulvovaginal Candidiasis (2007). Available at: <https://www.bashhguidelines.org/current-guidelines/all-guidelines/> (accessed August 2019).
41. Takahashi Y, Nagata N, Shimbo T *et al.* Upper gastrointestinal symptoms predictive of *Candida* esophagitis and erosive esophagitis in HIV and non-HIV patients: an endoscopy-based cross-sectional study of 6011 patients. *Medicine (Baltimore)* 2015; **94**: e2138.
42. Stebbing J, Krown SE, Bower M *et al.* Primary esophageal carcinoma in the era of highly active antiretroviral therapy. *Arch Intern Med* 2010; **170**: 203–207.
43. Bonacini M, Laine L, Gal AA *et al.* Prospective evaluation of blind brushing of the esophagus for *Candida* esophagitis in patients with human immunodeficiency virus infection. *Am J Gastroenterol* 1990; **85**: 385–389.
44. Nishimura S, Nagata N, Shimbo T *et al.* Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy. *PLoS One* 2013; **8**: e58217.
45. Shiboski CH, Chen H, Secours R *et al.* High accuracy of common HIV-related oral disease diagnoses by non-oral health specialists in the AIDS Clinical Trial Group. *PLoS One* 2015; **10**: e0131001.
46. Denning DW, Perlin DS, Muldoon EG *et al.* Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities. *Emerg Infect Dis* 2017; **23**: 177–183.
47. Law D, Moore CB, Wardle HM *et al.* High prevalence of antifungal resistance in *Candida* spp. from patients with AIDS. *J Antimicrob Chemother* 1994; **34**: 659–668.
48. Maenza JR, Merz WG, Romagnoli MJ *et al.* Infection due to fluconazole-resistant *Candida* in patients with AIDS: prevalence and microbiology. *Clinical Infect Dis* 1997; **24**: 28–34.
49. Oxman DA, Chow JK, Frenzl G *et al.* Candidaemia associated with decreased in vitro fluconazole susceptibility: is *Candida* speciation predictive of the susceptibility pattern? *J Antimicrob Chemother* 2010; **65**: 1460–1465.
50. Cuenca-Estrella M, Verweij PE, Arendrup MC *et al.* ESCMID* guideline for the diagnosis and management of *Candida* diseases 2012: diagnostic procedures. *Clin Microbiol Infect* 2012; **18 Suppl 7**: 9–18.
51. Lindau ST, Hoffmann JN, Lundeen K *et al.* Vaginal self-swab specimen collection in a home-based survey of older women: methods and applications. *J Gerontol B Psychol Sci Soc Sci* 2009; **64 Suppl 1**: i106–i118.
52. Byadarahally Raju S, Rajappa S. Isolation and identification of *Candida* from the oral cavity. *ISRN Dent* 2011; 2011: 487921.

53. Fidel PL, Jr., Barousse M, Espinosa T *et al.* An intravaginal live *Candida* challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. *Infect Immun* 2004; **72**: 2939–2946.
54. Bianchi Porro G, Parente F, Cernuschi M. The diagnosis of esophageal candidiasis in patients with acquired immunodeficiency syndrome: Is endoscopy always necessary? *Am J Gastroenterol* 1989; **84**: 143–146.
55. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. *Cochrane Database Syst Rev* 2010; CD003940.
56. De Wit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. *Lancet* 1989; **1**: 746–748.
57. Esposito R, Uberti Foppa C, Cernuschi M. Treatment of HIV-positive patients with oropharyngeal and/or oesophageal candidiasis: the results of a double blind study. *Int Conf AIDS* 1989; **5**: 474. Abstract Th.B.P.348.
58. Smith DE, Gazzard BG. Fluconazole versus ketoconazole in oropharyngeal candidiasis in AIDS. *Lancet* 1989; **1**: 1130–1131.
59. Meunier F, Aoun M, Gerard M. Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomised double blind study of fluconazole versus ketoconazole. *Rev Infect Dis* 1990; **12 Suppl 3**: S364–S368.
60. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. *J Acquir Immune Defic Syndr* 1993; **6**: 1311–1316.
61. Sangeorzan JA, Bradley SF, He X *et al.* Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment and emergence of fluconazole resistance. *Am J Med* 1994; **97**: 339–346.
62. Hood S, Evans J, Bond J *et al.* The treatment of oropharyngeal candidiasis in HIV-infected patients with oral amphotericin B suspension. *AIDS Patient Care STDS* 1998; **12**: 625–627.
63. Vazquez JA, Patton LL, Epstein JB *et al.* Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety (SMILES). *HIV Clin Trials* 2010; **11**: 186–196.
64. Rautemaa R, Ramage G. Oral candidosis-clinical challenges of a biofilm disease. *Crit Rev Microbiol* 2011; **37**: 328–336.
65. Smith DE, Midgley J, Allan M *et al.* Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. *AIDS* 1991; **5**: 1367–1371.
66. Barbaro G, Barbarini G, Calderon W *et al.* Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. *Candida Esophagitis. Gastroenterology* 1996; **111**: 1169–1177.
67. Lake-Bakaar G, Tom W, Lake-Bakaar D *et al.* Impaired gastric acid secretion in AIDS. *Gastroenterology* 1987; **92**: 1488.
68. Lake-Bakaar G, Tom W, Lake-Bakaar D *et al.* Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). *Ann Intern Med* 1988; **109**: 471–473.
69. Cartledge JD, Midgley J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. *J Clin Pathol* 1997; **50**: 477–480.

70. Liu NN, Kohler JR. Antagonism of fluconazole and a proton pump inhibitor against *Candida albicans*. *Antimicrob Agents Chemother* 2016; **60**: 1145–1147.
71. Graybill JR, Vazquez J, Darouiche RO *et al*. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. *Am J Med* 1998; **104**: 33–39.
72. Cartledge JD, Midgley J, Gazzard BG. Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. *AIDS* 1997; **11**: 163–168.
73. Saag MS, Fessel WJ, Kaufman CA *et al*. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. *AIDS Res Hum Retroviruses* 1999; **15**: 1413–1417.
74. Vazquez JA, Skiest DJ, Nieto L *et al*. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. *Clin Infect Dis* 2006; **42**: 1179–1186.
75. Ahmad SR, Singer SJ, Leissa BJ. Congestive heart failure associated with itraconazole. *Lancet* 2001; **357**: 1766–1767.
76. Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. *J Infect* 2007; **55**: 287–299.
77. Skiest DJ, Vazquez JA, Anstead GM *et al*. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. *Clin Infect Dis* 2007; **44**: 607–614.
78. Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. *Antimicrob Agents Chemother* 2015; **59**: 1671–1679.
79. Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. *Clin Infect Dis* 2015; **61**: 1558–1565.
80. Perfect JR, Marr KA, Walsh TJ *et al*. Voriconazole treatment for less-common, emerging, or refractory fungal infections. *Clin Infect Dis* 2003; **36**: 1122–1131.
81. Ally R, Schürmann D, Kreisel W *et al*. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. *Clin Infect Dis* 2001; **33**: 1447–1454.
82. Villanueva A, Arathoon EG, Gotuzzo E *et al*. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. *Clin Infect Dis* 2001; **33**: 1529–1535.
83. Kartsonis N, DiNubile MJ, Bartizal K *et al*. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. *J Acquir Immune Defic Syndr* 2002; **31**: 183–187.
84. Villanueva A, Gotuzzo E, Arathoon EG *et al*. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. *Am J Med* 2002; **113**: 294–299.
85. de Wet N, Llanos-Cuentas A, Suleiman J *et al*. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. *Clin Infect Dis* 2004; **39**: 842–849.
86. Krause DS, Simjee AE, van Rensburg C *et al*. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. *Clin Infect Dis* 2004; **39**: 770–775.

87. Watson MC, Grimshaw JM, Bond CM *et al.* Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of vulvovaginal candidiasis (thrush): a systematic review. *BJOG* 2002; **109**: 85–95.
88. Davies S, Johnson E, White D. How to treat persistent vaginal yeast infection due to species other than *Candida albicans*. *Sex Transm Infect* 2012; **89**: 165–166.
89. Lavazzo C, Gkeges ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. *J Womens Health (Larchmt)* 2011; **8**: 1245–1255.
90. Sobel JD, Chaim W. Therapy of *Torulopsis glabrata* vaginitis: retrospective review of boric acid therapy. *Clin Infect Dis* 1997; **24**: 649–652.
91. Cornely OA, Bassetti M, Calandra T *et al.* ESCMID* guideline for the diagnosis and management of *Candida* diseases 2012: non-neutropenic adult patients. *Clin Microbiol Infect* 2012; **18 Suppl 7**: 19–37.
92. Takahashi Y, Nagata N, Shimbo T *et al.* Long-term trends in esophageal candidiasis prevalence and associated risk factors with or without HIV infection: lessons from an endoscopic study of 80,219 patients. *PLoS One* 2015; **10**: e0133589.
93. Berkeley JL, Nath A, Pardo CA. Fatal immune reconstitution inflammatory syndrome with human immunodeficiency virus infection and *Candida* meningitis: case report and review of the literature. *J Neurovirol* 2008; **14**: 267–276.
94. Barchiesi F, Hollis RJ, Del Poeta M *et al.* Transmission of fluconazole-resistant *Candida albicans* between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. *Clin Infect Dis* 1995; **21**: 561–564.
95. Cameron ML, Schell WA, Waskin HA *et al.* Azole resistant *Candida albicans* oesophagitis and oral candidiasis in patients with AIDS. *Int Conf AIDS* 1992; **8**: 63. Abstract PuB 7085.
96. Cartledge JD, Midgley J, Gazzard BG. Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case-control study. *Genitourin Med* 1997; **73**: 471–474.
97. Gilquin J, Lavarde V, Meggle F, Acar JF. Selection of fluconazole-resistant yeasts in AIDS patients under fluconazole prophylaxis. *Int Conf AIDS* 1990; **6**: 382. Abstract 2112.
98. Fox R, Neal KR, Leen CL *et al.* Fluconazole resistant *Candida* in AIDS. *J Infect* 1991; **22**: 201–204.
99. Powderly WG. Mucosal candidiasis caused by non-*albicans* species of *Candida* in HIV-positive patients. *AIDS* 1992; **6**: 604–605.
100. Fulton P, Phillips P. Fluconazole resistance during suppressive therapy of AIDS-related thrush and oesophagitis caused by *Candida albicans*. *Int Conf AIDS* 1990; **6**: 239. Abstract Th.B.468.
101. Kitchen VS, Savage M, Harris JR. *Candida albicans* resistance in AIDS. *J Infect* 1991; **22**: 204–205.
102. Just-Nübling G, Gentschew G, Meissner K *et al.* Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. *Eur J Clin Microbiol Infect Dis* 1991; **10**: 917–921.
103. Reynes J, Mallie M, Bastide JM *et al.* In vitro susceptibility of *Candida albicans* isolates from HIV-infected patients with relapse of thrush during fluconazole long-term therapy. *Int Conf AIDS* 1991; **7**: 271. Abstract W.B.2357.
104. Goldman M, Cloud GA, Wade KD *et al.* A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. *Clin Infect Dis* 2005; **41**: 1473–1480.

105. Bower M, Palfreeman A, Alfa-Wali M *et al.* British HIV Association guidelines for HIV-associated malignancies 2014. *HIV Med* 2014; **15 Suppl 2**; 1–92.

8 Acknowledgements

The writing group thanks Ms Rosy Weston, Senior Lead Pharmacist for Sexual Health and HIV at Imperial College Healthcare NHS Trust, for performing a pharmacy review, Dr Jacoby Patterson for conducting independent literature searches and Dr Catherine Nieman Sims for supporting manuscript preparation. The writing group also thanks the HIV community, professional colleagues who contributed to the consultation and the reviewers for helpful comments.

Appendix 1: PICO questions

- 2 What is the epidemiology of candidiasis in individuals living with HIV?
- 2.1 What are the main *Candida* spp. causing *Candida* infections in recent surveys of people living with HIV?
- 2.2 What are the main risk factors for *Candida* infection in people living with HIV?
- 3.1 What are the clinical manifestations of mucosal candidiasis in people living with HIV?
- 4.1 When is it appropriate to request microbiological confirmation of *Candida* infections?
- 4.2 What are the preferred techniques for microbiological diagnosis of *Candida* spp.?
- 4.3 When should endoscopy be used to diagnose suspected oesophageal candidiasis?
- 5.1a What are the preferred treatments for oropharyngeal candidiasis?
- 5.1b What is the role of topical therapy?
- 5.2. What are the preferred treatments for oesophageal candidiasis?
- 5.3 How should fluconazole-refractory candidiasis be treated?
- 5.4 What are the preferred treatments for vulvovaginal candidiasis?
- 5.5 How should invasive candidiasis be treated in people living with HIV?
- 6.1 Is prophylaxis to prevent mucosal candidiasis recommended for people with advanced HIV infection?
- 6.2 Is continuous azole therapy recommended?

Appendix 2: Search strategy

1. Candida and HIV

1	exp "Candida"/ [MESH, all subheadings]
2	Candida or "Candidiasis" [text]
3	1 or 2
4	HIV (MESH and text)
5	3 and 4
6	Limit to dates: 2010 to date of search (March 2018)

2. Candida and diagnostics

1	exp "Candida"/ [MESH, explode]
2	HIV (MESH and text)
3	exp "Diagnosis"/
4	1 and 2 and 3
5	Limit to dates: 2010 to date of search (March 2018)

3. Candida and treatment

1	exp "Candida"/ [MESH, explode]
2	HIV (MESH and text)
3	exp "Treatment"/
4	1 and 2 and 3
5	Limit to dates: 2010 to date of search (March 2018)

Appendix 3: Definitions

Person living with HIV: an individual with a positive serological test for HIV

Oropharyngeal candidiasis: clinical appearance of candidiasis in the mouth or throat with non-adherent or adherent plaques, areas of erythema or cracking or erythema at the angles of the mouth in the presence or absence of symptoms such as pain and burning. Where microbiological testing has been performed it should reveal *Candida* spp. or in their absence fail to identify an alternative micro-organism

Oesophageal candidiasis: pain or difficulty swallowing, usually in the presence or with features of oropharyngeal candidiasis with or without endoscopic confirmation. Where microbiological testing has been performed it should reveal *Candida* spp. or in their absence fail to identify an alternative micro-organism

Vulvovaginal candidiasis: a clinical diagnosis of redness, itching or curd-like discharge from the vulva with or without associated symptoms such as dyspareunia and external dysuria in association with identification of yeasts on microscopy or culture

Invasive candidiasis: microbiological identification of *Candida* spp. by culture from a normally sterile site such as the blood

Prophylaxis: an intervention performed to prevent development of a clinical syndrome associated with disease

Appendix 4: Summary of selection of literature

